Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: The Royal Marsden Hospital experience

Haematologica

Volumn 92, Issue 2, 2007, Pages 271-272

  Arkenau, Hendrik Tobias ^a   Chong, Geoff ^a   Cunningham, David ^a   Watkins, David ^a   Sirohi, Bhawna ^a   Chau, Ian ^a   Wotherspoon, Andrew ^b   Norman, Andy ^a   Horwich, Alan ^a   Matutes, Estella ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cisplatin; GEM P; Gemcitabine; Methylprednisolone; PTCL; T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; LEUCOPROLEN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MONOTHERAPY; NEUTROPENIA; T CELL LYMPHOMA; TREATMENT RESPONSE; ADOLESCENT; LETTER; MIDDLE AGED; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33947512466     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10737     Document Type: Article

References (10)

1. Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS. Diagnosis and actual strategies in peripheral T-cell lymphomas: summary of an international meeting. Ann Oncol 2004; 15:369-74.
2. Cheng AL, Chen YC, Wang CH, Su IJ, Hsieh HC, Chang JY, et al. Direct comparison of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades- should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7:725-31.
3. Grigg A. Daclizumab in anaplastic large cell lymphoma. Leuk Lymphoma 2006;47:175.
4. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 2005; 19:1648-55.
5. Weidmann E, Hess G, Krause SW. Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin is an effective firstline regimen in peripheral T-cell lymphoma. Blood 2004; 104:2640[Abstract].
6. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603-6.
7. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-41.
8. Kim JG, Sohn KS, Chae YS, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006;58:35-9.
9. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, et al. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004;5:45-9.
10. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92:1352-7.